

### **Additional Inclusion Criteria for UC Subjects**

- 30. Pathologically or cytologically documented unresectable or metastatic UC of the bladder, renal pelvis, ureter, or urethra. Subjects with histological variants are allowed if urothelial histology is predominant. Small cell/neuroendocrine tumors are not allowed even if mixed histology.
- 31. Relapse or progression after at least 1 prior line of ICI-containing systemic therapy and 1 prior line of systemic chemotherapy, given in combination with other anticancer therapy or separately, with a maximum of 3 prior therapy lines.
  - a. At least 1 line of therapy should include enfortumab vedotin in countries where enfortumab vedotin is approved and available.
  - b. Perioperative systemic therapies will be counted as 1 line of therapy.
  - c. To meet inclusion criteria requirement of prior ICI-containing therapy, use in the perioperative or metastatic setting will suffice.
  - d. Subjects with actionable target tumor mutation should have been previously treated with targeted therapy.
  - e. The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy.